In 2024, Getein ACHieved annual revenue of RMB 1.165 billion, with chemiluminescence business growing 31.14% to RMB 265 million. The company was recognized as a national high-tech enterprise (GR202432016598) in December 2024, qualifying for a 15% preferential corporate income tax rate for three years. For the first three quarters of 2025, revenue reached RMB 758 million, with Q3 net profit surging 80.83% year-over-year. The Metis6000 automated chemistry-immunoassay pipeline has accumulated nearly 70 installations nationwide, with over 50% deployed in secondary and tertiary hospitals.
Company Profile (Updated April 2026)
Getein Biotech, Inc. (基蛋生物科技股份有限公司) is a leADINg Chinese in vitro diagnostics (IVD) company headquartered in Nanjing, Jiangsu Province, China. Founded in March 2002 by Dr. Su Enben (苏恩本)—a former clinical physician and chief physician in the Cardiology Department of Jiangsu Provincial People's Hospital—the company was successfully listed on the Shanghai Stock Exchange (Ticker: 603387) in July 2017.
Development History:
- 2002: Established in Nanjing, focusing on POCT diagnostic reagents and instruments
- 2014: Reorganized into a joint-stock company (December 18)
- 2017: Successfully listed on the Shanghai Stock Exchange Main Board (603387)
- 2022: Launched the Metis6000 automated chemistry-immunoassay pipeline system, integrating biochemical and chemiluminescence modules
- 2023: Released the Metis800 agile series pipeline (hematology + immunofluorescence + chemiluminescence); Metis6000 installations approached 70 units
- 2024: Annual revenue RMB 1.165 billion; chemiluminescence revenue reached RMB 265 million (+31.14%); obtained national high-tech enterprise certification (GR202432016598); subsidiary Wuhan Jingchuan Diagnostics removed from consolidated financial statements due to shareholder disputes (July 1)
- 2025: Q3 net profit increased 80.83% YoY; continued expansion of chemiluminescence terminal coverage; MAGICL platform detection items reached 107
Core Mission: "Pursue Excellence, Deliver Health"—committed to becoming an internationally competitive biotechnology company through continuous innovation in diagnostic technologies.
Core Technology Platforms
Getein has developed eight core technology platforms covering the full spectrum of IVD disciplines:
- Point-of-Care Testing (POCT): Immunofluorescence quantitative analyzers and test kits—company's traditional strength and market-leading segment
- Chemiluminescence Immunoassay (CLIA): High-sensitivity, high-throughput automated chemiluminescence systems for cardiac, inflammation, thyroid, tumor markers, and more
- Clinical Chemistry: Fully automated biochemical analyzers for liver function, kidney function, lipids, and metabolic panels
- Hematology: Blood cell analysis systems for complete blood count (CBC) and related parameters
- Coagulation: Automated coagulation analyzers (CA5700/CA5500) for thrombosis and hemostasis testing
- Urinalysis: Automated urine microscopy and chemistry analysis systems
- Molecular Diagnostics: Nucleic acid amplification and detection platforms (GN 7120/GN 7000)
- Diagnostic Raw Materials: Independent development and production of key biological raw materials to ensure supply chain security and cost control
Core Products & Solutions
Chemiluminescence Systems (Core Growth Engine)
Chemiluminescence has become Getein's Primary growth driver, with revenue increasing 31.14% in 2024 to RMB 265 million, accounting for 26.72% of self-produced product revenue:
- MAGICL6000 / MAGICL6000i: Compact chemiluminescence analyzers (small-light platforms) with over 960 new installations in 2024; cardiac and inflammation tests account for over 55% of test volume
- MAGICL6200: Mid-to-high throughput chemiluminescence analyzer with 400 tests/hour throughput
- MAGICL8500: High-throughput system supporting 600 tests/hour with 1-4 unit cascade capability
- MAGICL8200: Compact, agile chemiluminescence analyzer for flexible deployment
- Test Menu: As of end-2024, 107 chemiluminescence test items covering cardiovascular, inflammation, thyroid, tumor markers, metabolism, hormones, and more—essentially covering all common clinical disease categories
Automated Pipeline Systems
- Metis6000: Fully automated chemistry-immunoassay pipeline integrating the MAGICL6200 immunoassay module and CM-1000 biochemistry module; footprint only 2.6 square meters; accumulated nearly 70 installations with over 50% in secondary and tertiary hospitals
- Metis800 Agile Series: Innovative pipeline combining hematology, immunofluorescence, and chemiluminescence modules for flexible, scalAble laboratory automation
- Metis7000: Next-generation pipeline system under development
Clinical Chemistry
- CM-1000: Fully automated biochemistry analyzer with 1,000 tests/hour throughput, supporting comprehensive metabolic, liver, kidney, and lipid panels
POCT Systems (Traditional Strength)
- FIA Series: Quantitative immunofluorescence analyzers for Rapid cardiac marker, inflammation, and renal function testing at the point of care
- Cardiac Marker Test Kits: Rapid quantitative detection of cTnI, MYO, CK-MB, NT-proBNP, D-Dimer, and other cardiovascular biomarkers
- Getein 1100 / 1600: Portable POCT analyzers for emergency departments, primary care, and bedside testing
Coagulation Systems
- CA5700: Fully automated coagulation analyzer with 400 tests/hour throughput; features automated track, auto-dilution, auto-rerun, barcode recognition, reagent needle heating, APTT correction experiments, and HIL interference alerts
- CA5500: Compact fully automated coagulation analyzer with foldable display; suitable for small-to-medium laboratories
Molecular Diagnostics
- GN 7120 / GN 7000: Fully automated nucleic acid amplification analyzers for molecular POCT applications
Financial Performance
2024 Annual Results
- Total Revenue: RMB 1,164.80 million (~USD 162 million), down 14.93% YoY (primarily due to declines in POCT and agency product revenue amid industry-wide demand changes)
- Net Profit Attributable to Parent: RMB 223.64 million, down 20.06% YoY
- Non-Recurring Net Profit: RMB 202.04 million, down 16.33% YoY
- Basic EPS: RMB 0.44
- Operating Cash Flow: RMB 423.00 million, up 26.94% YoY (driven by supply chain optimization and cost controls)
- Total Assets: RMB 3,707.37 million
- Net Assets Attributable to Parent: RMB 2,618.96 million
- Weighted Average ROE: 8.64%
2025 First Three Quarters Results
- Revenue: RMB 757.69 million, down 13.88% YoY
- Net Profit Attributable to Parent: RMB 160.54 million, down 8.48% YoY (improved decline vs. full-year 2024)
- Non-Recurring Net Profit: RMB 134.53 million, down 9.96% YoY
- Operating Cash Flow: RMB 235.29 million
- Basic EPS: RMB 0.32
- Weighted Average ROE: 6.00%
2025 Q3 Single Quarter (Notable Recovery)
- Revenue: RMB 245.00 million, down 6.55% YoY (narrowed decline)
- Net Profit Attributable to Parent: RMB 51.74 million, up 80.83% YoY (significant recovery)
- Non-Recurring Net Profit: RMB 41.30 million, up 117.52% YoY
2025 First Half Results
- Revenue: RMB 512.69 million, down 17.00% YoY
- Net Profit Attributable to Parent: RMB 108.81 million, down 25.88% YoY
- R&D Investment: RMB 83.49 million, accounting for 16.28% of revenue
- Revenue by Business: Self-produced products RMB 446.47 million; Third-party inspection collaboration and others RMB 66.22 million
- Revenue by Region: Domestic RMB 439.60 million; International RMB 73.09 million
Strategic Focus & Market Position
Business Segmentation
Getein's revenue composition reflects a strategic shift from traditional POCT to comprehensive IVD platform solutions:
- Self-Produced Products: Core business including POCT, chemiluminescence, clinical chemistry, hematology, coagulation, and molecular diagnostics
- Third-Party Inspection Collaboration: Laboratory collaboration and joint ventures with medical institutions
- International Markets: Products exported to 110+ countries and regions; international revenue accounted for approximately 14% of H1 2025 revenue
Competitive Advantages
- Platform Diversification: Eight technology platforms provide comprehensive laboratory solutions and reduce single-segment risk
- Chemiluminescence Momentum: Fastest-growing segment (+31.14% in 2024) with expanding test menu and terminal coverage
- Pipeline Innovation: Metis6000/Metis800 automated pipeline systems address the growing demand for laboratory automation in china's healthcare system
- Raw Material Self-Sufficiency: Independent production of key biological raw materials ensures cost control and supply chain security
- Service Network: 28 after-sales service outlets nationwide with 24-hour equipment restoration commitment
Company Information & Leadership
Corporate Overview
Company Full Name: Getein Biotech, Inc. (基蛋生物科技股份有限公司)
Founded: March 8, 2002
Headquarters: No. 9 Bofu Road, Yanjiang Industrial Development Zone, Luhe District, Nanjing, Jiangsu 211505, China
Stock Exchange: Shanghai Stock Exchange Main Board
Ticker Symbol: 603387
Company Type: Public listed company (A-share)
Industry: Medical Devices - In Vitro Diagnostics (IVD)
Employees: Nearly 2,000
Subsidiaries: 35+ worldwide
Certifications: ISO 13485, MDSAP, ISO 9001, CE, National High-Tech Enterprise (GR202432016598)
Leadership Team
Founder, Chairman & General Manager: Dr. Su Enben (苏恩本)
- Born 1966; Ph.D. in Medicine
- Former clinical physician and chief physician at Jiangsu Provincial People's Hospital Department of Cardiology
- Founded Getein Biotech in 2002; led the company from startup to SSE listing in 2017
- Also serves as executive director/chairman of multiple affiliated companies including Getein Holding Group and Jiangsu Aolite New Materials
- Controlling shareholder and actual controller of the company
Board Secretary: Liu Ci (刘慈)
Chief Financial Officer / Accounting Officer: Ni Wen (倪文)
Supervisor: Tao Aidi (陶爱娣)
2026 Outlook & Strategic Focus
Future Development Priorities
- Chemiluminescence Expansion: Continue rapid expansion of MAGICL platform installations and test menu coverage; target further penetration in secondary and tertiary hospitals
- Pipeline Automation: Scale Metis6000 and Metis800 installations to capture China's growing demand for integrated laboratory automation solutions
- International Growth: Strengthen export channels to 110+ existing markets and expand presence in Southeast Asia, South Asia, and other emerging regions
- Product Diversification: Advance development in molecular diagnostics, coagulation, and urinalysis to achieve more balanced revenue across all eight technology platforms
- Cost Optimization: Continue supply chain optimization and intelligent expense management systems to improve profitability amid industry headwinds
- Resolution of Jingchuan Dispute: Address ongoing shareholder disputes with Wuhan Jingchuan Diagnostics minority shareholders through legal and governance channels
Contact Information
China Headquarters
Address: No. 9 Bofu Road, Yanjiang Industrial Development Zone, Luhe District, Nanjing, Jiangsu 211505, China
Telephone: +86-25-68568577
Email (IR): IR@gtein.cn
Email (Sales): sales@getein.com.cn
Website: www.getein.com.cn (Chinese)
Global Website: www.getein.com (English)
Investor Relations
Stock Exchange: Shanghai Stock Exchange Main Board
Ticker: 603387
Disclosure Newspaper: Shanghai Securities News
Auditor: Gongzheng Tianye Certified Public Accountants (Special General Partnership)
Keywords: Getein Biotech, 基蛋生物, 603387, POCT, point-of-care testing, IVD, in vitro diagnostics, chemiluminescence, MAGICL, clinical chemistry, hematology, coagulation, molecular diagnostics, urinalysis, Metis6000, MAGICL6000, MAGICL6200, MAGICL8500, CM-1000, Nanjing, China, Su Enben, 苏恩本, cardiac markers, immunofluorescence, high-tech enterprise, ISO 13485, CE, Shanghai Stock Exchange, automated pipeline, biochemistry analyzer, GN 7120, CA5700, CA5500, FIA8000, cTnI, D-Dimer, NT-proBNP, third-party inspection, Jingchuan Diagnostics
